BeyondSpring will present on Plinabulin at the IO360° Conference, discussing its mechanism in overcoming cancer treatment resistance.
Quiver AI Summary
BeyondSpring Inc. announced its participation in the upcoming Immuno-Oncology 360° Conference 2026, taking place from February 10-12 in Boston, MA. Dr. Lan Huang, the company's CEO, will present on their drug Plinabulin, which is designed to enhance the effectiveness of PD-1/PD-L1 inhibitors and features a unique mechanism of action. The presentation, titled "Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin," is scheduled for February 11 from 4:55 PM to 5:10 PM ET. After the presentation, slides will be available on the company’s website. BeyondSpring focuses on developing innovative therapies to meet significant medical needs, with Plinabulin as its leading candidate in late-stage clinical development for non-small cell lung cancer and other conditions.
Potential Positives
- Participation in the Immuno-Oncology 360° Conference highlights the company's commitment to advancing its research and gaining visibility in the oncology field.
- Dr. Lan Huang's presentation on Plinabulin showcases the company's innovative approach to cancer treatment, potentially attracting interest from investors and collaborators.
- Availability of presentation materials on the company's website underscores transparency and enhances engagement with stakeholders.
Potential Negatives
- Company is still in clinical-stage development, indicating that their product has not yet reached the market, which may raise concerns about long-term viability and investor confidence.
- Plinabulin's clinical development strategy may face scrutiny given that it targets overcoming PD-1/PD-L1 resistance, a competitive and complex area in immuno-oncology.
FAQ
What is BeyondSpring Inc. presenting at the IO360° Conference 2026?
BeyondSpring will present on Plinabulin, focusing on its role in enhancing PD-1/PD-L1 blockade.
When is BeyondSpring's presentation scheduled?
The presentation is scheduled for February 11, 2026, from 4:55 PM to 5:10 PM ET.
Where will the IO360° Conference 2026 take place?
The conference will be held in Boston, MA, at the Sheraton Boston Hotel.
How can I access the presentation slides?
The slides will be available on the "Posters and Presentations" page of BeyondSpring's website after the presentation.
What are the key features of Plinabulin?
Plinabulin is a dendritic cell maturation agent that offers unique anti-cancer activity and immune modulation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BYSI Insider Trading Activity
$BYSI insiders have traded $BYSI stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.
Here’s a breakdown of recent trading of $BYSI stock by insiders over the last 6 months:
- CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. DECHENG has made 0 purchases and 46 sales selling 460,179 shares for an estimated $815,899.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BYSI Hedge Fund Activity
We have seen 8 institutional investors add shares of $BYSI stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DECHENG CAPITAL LLC removed 245,377 shares (-5.4%) from their portfolio in Q3 2025, for an estimated $444,132
- VANGUARD GROUP INC added 212,254 shares (+38.8%) to their portfolio in Q4 2025, for an estimated $345,974
- GEODE CAPITAL MANAGEMENT, LLC added 59,272 shares (+23.1%) to their portfolio in Q3 2025, for an estimated $107,282
- NORTHERN TRUST CORP added 54,469 shares (+334.0%) to their portfolio in Q3 2025, for an estimated $98,588
- BLACKROCK, INC. added 4,573 shares (+0.7%) to their portfolio in Q3 2025, for an estimated $8,277
- TOWER RESEARCH CAPITAL LLC (TRC) added 1,189 shares (+470.0%) to their portfolio in Q3 2025, for an estimated $2,152
- UBS GROUP AG added 901 shares (+67.3%) to their portfolio in Q4 2025, for an estimated $1,468
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026 , held February 10-12, 2026 in Boston, MA.
Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical development strategy.
Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science & Biomarkers – Expanding Therapeutic Horizons
Date: Wednesday, February 11, 2026
Time: 4:55PM to 5:10PM ET
Location: Sheraton Boston Hotel, Track 1, Grand Ballroom
Following the presentation, the slides will also be available on the “Posters and Presentations” page of the Company’s website.
About BeyondSpring
BeyondSpring
(NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at
https://beyondspringpharma.com
.
Investor Contact:
[email protected]
Media Contact:
[email protected]
